Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced the voting results from its Annual General Meeting of Shareholders held on Monday, June 26, 2023, in Madrid.
June 27, 2023
· 7 min read